LSK Global PS
LSK Global PS is a privately held Korean full-service Contract Research Organization providing end-to-end clinical trial, regulatory, data management, biostatistics, and pharmacovigilance services to domestic and international pharmaceutical and biotech sponsors, with overseas branches in Taiwan and Poland.
- Company typePrivate
- Founded2000
- HeadquartersSeoul, South Korea
- Headcount251–500
- GTM typeB2B
- OfferingServices
What LSK Global PS does
LSK Global PS (legal name: LSK Global Pharma Services Co., Ltd.) is a Korea-headquartered, full-service Contract Research Organization providing end-to-end clinical development services for pharmaceutical and biotech sponsors. The company originated in 2000 as Westat Korea, became Lifecord Stat-Korea, Inc. in 2001, and adopted its current name in 2006. It serves as a one-stop CRO covering the entire drug development lifecycle across 14 service modules: consulting, medical services, medical writing, regulatory affairs, project management, study start-up, clinical operations, data management, biostatistics, post-marketing surveillance/observational studies, pharmacovigilance, quality assurance, academic research services, and training. Its customer base spans domestic Korean pharma, international pharma with Korea programs, and Korean biotech pursuing global development, with named enterprise relationships including GC Corp, INT Therapeutics, and Daewoong Pharmaceutical.
The technology stack is anchored on best-in-class third-party platforms — Medidata Rave, Target e*Studio, Oracle InForm, Oracle Argus, Veeva Vault, Medidata CTMS, Medidata Intelemage, ArisGlobal Safety Database, and the MediLake CDISC platform — supplemented by LSK's proprietary LSK V1Z data visualization tool. The company is a Medidata channel partner and a CDISC member, with FDA 21 CFR Part 11 compliant systems and direct US FDA SDTM submission experience. Wholly-owned subsidiaries (LSK NRDO, LSK SMO) and overseas branches (LSK Taiwan for data management; LSK PV EU in Warsaw, Poland for European pharmacovigilance) support its global delivery model, alongside the Asia CRO Alliance and partner CRO networks across North America, EU, Japan, China, and Southeast Asia.
The business model is project-based, professional-services revenue earned through direct enterprise contracts negotiated by the Business Development department. Pricing is quote-based and customized by indication, phase, site count, and subject count, with multi-year contract cadences typical of full-service CRO engagements. The company holds a stack of "first-in-Korea" regulatory certifications (ISO 9001, 37001, 37301, 27001, 14155, CCDM Industry Partner, KoNECT Innovative CRO) plus the only EMA direct-reporting pharmacovigilance qualification among Korean CROs, all of which are actively renewed (most recently ISO 27001 in January 2026 and family-friendly certification in 2026). The company is privately held with no disclosed external investors or parent company, founded and led by Young Jack Lee, a former NIH Biostatistics Branch Chief.
LSK Global PS firmographics
Firmographics- Name
- LSK Global PS
- Legal name
- LSK Global Pharma Services Co., Ltd.
- Website
- https://lskglobal.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- LSK Global PS is a privately held Korean full-service Contract Research Organization providing end-to-end clinical trial, regulatory, data management, biostatistics, and pharmacovigilance services to domestic and international pharmaceutical and biotech sponsors, with overseas branches in Taiwan and Poland.
- Ownership category
- akta.pro rank
LSK Global PS industry classification
Industry- Product category
- Contract Research Organization (CRO) Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
Keywords
Where LSK Global PS is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
LSK Global PS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Services: Full-service CRO providing Phase I-III registration trials, investigator-initiated studies, Phase IV and post-marketing surveillance, observational studies, and consulting services for new drug development. Revenue generated through project-based contracts with pharmaceutical and biotech sponsors.
- Regulatory Affairs Services: IND/NDA package preparation, submission, regulatory authority review management, and approval support. Includes US FDA, EMA, and Korean MFDS regulatory strategy consulting.
- Pharmacovigilance Services: Safety monitoring, ICSR processing, PSUR/PBRER development, PV audit, and Eudravigilance reporting services. Includes EMA direct reporting capabilities.
- Education and Training Services: Clinical trial monitor training programs approved by MFDS, including CRA training, QA training, and customized training for pharmaceutical companies and institutions.
- Academic Research Services: Research design, data management, statistical analysis, manuscript writing, and statistical consulting for pharmaceutical and medical academic research.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based custom pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
LSK Global PS product offering
Product offeringCore offering
LSK Global PS is a full-service Contract Research Organization (CRO) providing end-to-end clinical drug development services for pharmaceutical and biotech sponsors. The company delivers an integrated platform covering the entire clinical trial lifecycle—from drug development consulting, regulatory affairs, medical writing, and study start-up through Phase I–IV clinical operations, data management, biostatistics, pharmacovigilance, quality assurance, and post-marketing surveillance. Services are sold via custom project-based contracts negotiated through the Business Development department.
Product overview
LSK Global PS operates as a comprehensive one-stop full-service CRO (Contract Research Organization) platform providing end-to-end clinical development services from early consulting through post-marketing surveillance. The platform is organized around 14 integrated service modules: Drug Development Consulting, Medical Service, Medical Writing, Regulatory Affairs, Project Management, Study Start-Up, Clinical Operation, Data Management, Biostatistics, Epidemiological Research for PMS/OS, Pharmacovigilance, Quality Assurance, Academic Research Service (ARS), and Training. Key technology-enabled service components include Medidata Rave EDC, Oracle InForm, Oracle Argus safety management, Target e*Studio eCRF, Veeva Vault Clinical Applications, and the proprietary LSK V1Z data visualization tool. LSK Global PS is a Medidata Channel Partner and CDISC member, with an EU pharmacovigilance branch in Warsaw, Poland and a Data Management branch in Taiwan.
Differentiator
Problem solved
Functional benefit
Products and services
- Full-Service CRO Platform Comprehensive one-stop full-service CRO platform covering the entire drug development lifecycle from initial consulting and preclinical strategy through Phase I–IV clinical trials, post-marketing surveillance, and observational studies. Integrates consulting, regulatory affairs, clinical operations, data management, biostatistics, pharmacovigilance, and training services for pharmaceutical and biotech sponsors.
- Drug Development Consulting Service
- Medical Service
- Medical Writing Service Ethical and scientific protocol development for Phase I–IV clinical studies, medical device trials, health functional food studies, observational studies, and post-marketing surveillance. Also produces clinical study reports including statistical analysis and clinical interpretation.
- Regulatory Affairs Service Regulatory affairs support covering domestic and international regulations for clinical trial conduct and product registration, including IND/NDA package preparation, FDA/MFDS regulatory strategy, and EMA regulatory management.
- Project Management Service Comprehensive project management including planning, timeline management, quality management, risk management, and vendor management to coordinate clinical trials from initiation to close-out.
- Study Start-Up Service Specialized study start-up services including feasibility assessment, IRB initial submission, site budget negotiation, and clinical trial agreement execution, managed by dedicated SSU specialists.
- Clinical Operation Service Full site management covering pre-study visits, initiation visits, regular monitoring, and close-out visits, employing risk-based monitoring, centralized monitoring, and on-site monitoring approaches.
- Data Management Service Full-service clinical data management from CRF development through CDM system configuration, operation, and management. Includes eCRF design, Medidata Rave and Oracle InForm EDC systems, medical coding (MedDRA/WHODrug), SAE reconciliation, CDISC SDTM/ADaM conversion, and LSK V1Z data visualization. LSK Global PS is a Medidata Channel Partner and CDISC member.
- Biostatistics Service Comprehensive biostatistics services including study design, sample size calculation, statistical analysis plan development, CDISC ADaM dataset generation, statistical programming (SAS), TFL production, and analysis report writing. Staffed by 6 PhD statisticians and multiple senior statisticians.
- Epidemiological Research for PMS/OS Service Specialized post-marketing observational study services including regulatory PMS, reexamination studies, prospective and retrospective observational studies, surveys, and chart reviews, delivered by a dedicated epidemiological research department established in 2010.
- Pharmacovigilance Service Comprehensive PV services from first-in-human through post-marketing, including SAE processing, ICSR management, PSMF, DSUR, PBRER, RMP, EudraVigilance direct reporting, and PV audit. Includes a dedicated EU branch in Warsaw, Poland, established May 2019, enabling direct EMA safety reporting. LSK Global PS holds the only EMA direct-reporting qualification among Korean CROs.
- Quality Assurance Service ICH-GCP-based independent audits, internal quality management, vendor assessment, SOP development, and consulting services. All QA auditors hold RQAP-GCP certification.
- Academic Research Service (ARS) Full-cycle academic research support from study planning and design through data management, statistical analysis, and manuscript publication. Includes EDC-based study management, SAP development, and statistical consulting for academic medical researchers.
- Training Service Systematic education programs for clinical research professionals including CRA (monitor) training, QA training, biostatistics workshops, and customized corporate training. LSK Education Center is MFDS-designated as a clinical trial education institution since August 2016.
- LSK V1Z Data Visualization Service Proprietary tailored clinical data visualization and reporting service that transforms complex clinical trial data into intuitive visual reports using graphs, color-coded indicators, and interactive dashboards to support monitoring, early risk signal detection, and data-driven decision-making.
- Oracle Argus Safety Case Management Solution Pharmacovigilance safety case management service powered by Oracle Argus, processing over 10 million safety cases annually with AI-powered features designed to enhance efficiency and data privacy.
Quantifiable outcome
- Surpassed 1,000 clinical trial contracts milestone in 2018
- +1 more outcomes
Companies that use LSK Global PS
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
LSK Global PS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
AI capability4 records
Feature8 records
LSK Global PS partnerships and signals
Strategic signalPartnerships
24 partnerships are on record, tiered core and minor.
- 원스글로벌 (ONES Global)coreMOU for data-based clinical research cooperation. Aims to enhance successful execution and capacity building for clinical trials and new drug development through evidence-based approaches.
- Certara KoreacoreMOU for strengthening clinical trial and regulatory strategy. Collaboration to enhance new medicine development and regulatory expertise.
- 서울대학교병원minorCDISC Seoul Interchange 2024 session presentation on CDISC standard utilization.
- 서울아산병원 항암유효성평가지원센터 (APEX)coreMOU for enhancing new drug commercialization success rate and fulfilling efficacy evaluation demand. Joint symposiums on next-generation oncology conducted annually.
- 중앙대학교minorMOU for activation and development of medical statistics and clinical trial field cooperation.
- 재인알앤피 (Jaein RNL)minorStrategic MOU for new drug development and global clinical research cooperation.
- 아주대병원minorMOU for activation of domestic medical device clinical trials.
- 고려대학교 구로병원minorMOU for domestic pharmaceutical and medical device clinical trial development.
- 연세의료원 연구개발자문센터minorMOU for healthcare big data utilization in clinical research.
- 건국대학교 산학협력단minorMOU for establishing industry-academia cooperation system.
- 뉴클릭스바이오 (Nuclix Biosciences)minorMOU for innovative anticancer drug development based on prototype mRNA technology.
- 대웅제약 (Daewoong Pharmaceutical)coreMOU for joint clinical development cooperation of COVID-19 treatment 'Foistar Tab' (Camostat Mesylate).
- 질병관리청coreJoint development partner with GC녹십자 for world's first recombinant anthrax vaccine '배리트락스주'. Awarded Grand Prize at 27th Korea New Drug Development Awards.
- 고려대학교 의료원 산학협력단minorMOU for clinical trial industry cultivation and mutual cooperation.
- 연세대학교 의과대학 강남세브란스병원coreMOU for clinical trial cooperation and research outcomes partnership.
- 타겟헬스 (Target Health)coreClinical research and regulatory consulting partnership. Joint seminars conducted annually including LSK Global PS year-end conference.
- 지엔티파마 (GNT Pharma)minorStrategic partnership for joint new drug research and development.
- 켐온 (Chemon)minorStrategic partnership for non-clinical service CRO cooperation to maximize joint research and development capabilities.
- DKSH KoreaminorMOU for strategic expansion of pharmaceutical market services.
- Asia CRO Alliance (ACA)coreAsia CRO Alliance comprising CROs from Korea, Japan, Taiwan, Vietnam, Malaysia. Provides understanding of local regulatory requirements and clinical trial environments across Asia.
- MakroCareminorAlliance agreement for global clinical development support.
- Medidata Solutions, InccoreChannel partner agreement for clinical technology solutions including CTMS, eTMF, and Intelemage imaging services.
- MDS Pharma Services (Canada)minorPartnership for clinical research services.
- Westat IncminorOriginal parent company partnership. LSK Global PS originated as Westat Korea branch before becoming independent.
Scale indicators9 records
Recent moves12 records
Expansion highlights6 records
LSK Global PS competitors and assessment
Company assessmentBroad incumbents
- Parexel International: Major global CRO with strong APAC presence and oncology/biotech focus; competes with LSK for Korean pharma globalization programs. Comparable on full-service clinical, regulatory, PV, and biopharma services.
- ICON plc: Global full-service CRO (post-PRA Health Sciences merger) competing head-to-head with LSK on Phase I-IV multinational trials. Comparable on data management (Medidata-academic) and oncology/biotech client segments.
- Syneos Health: Large global clinical and commercial solutions provider. Comparable functional overlap with LSK across Phase I-IV operations, biostatistics, PV, and consulting for global pharma/biotech sponsors.
- Labcorp Drug Development (Fortrea): Post-Labcorp spin-off global CRO covering clinical development, central labs, and PV — comparable to LSK's Medidata/CDISC data management, central laboratory experience, and global trial capabilities.
- IQVIA Holdings: Largest global CRO/C DMO with end-to-end clinical and real-world evidence services; competes with LSK for multinational sponsors and is expanding in Korea/APAC. Comparability via full-service clinical operations, data management, and PV offerings.
Direct peers
- Medpace Holdings: Mid-to-large global CRO with strong oncology, regulatory, and biostatistics capabilities — most direct functional overlap with LSK's full-service Phase I-IV offering, including proprietary technology platforms and PhD-led operational model.
- MakroCare: Asia-focused CRO with global delivery network and strategic alliance with LSK since 2010 for global clinical development support. Directly comparable on Asia-centric multi-country trials and clinical operations.
Regional players
- CMIC Holdings: Japan's largest CRO, also operating as a CDMO with full-service clinical, PV, and consulting capabilities. Closest Asia regional peer to LSK given comparable scale, multi-country coverage, and breadth of service modules.
Emerging players
- PSI CRO: Mid-sized global CRO with strong oncology/hematology focus and European/Asia footprint; comparable as a specialized full-service player competing for multinational biotech oncology and rare disease trials.
- Celerion: Early-phase clinical research specialist focused on FIH, PK/PD, and integrated clinical pharmacology. Comparable to LSK's early-phase oncology operations and FIH multinational trial experience.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
LSK Global PS social profiles
Digital presenceLSK Global PS compliance and trust
Trust signalCompliance10 records
LSK Global PS financial estimates
Financial estimateRevenue estimate
Valuation estimate
LSK Global PS leadership team
Management profileNumber of profiles
Profiles10 records
LSK Global PS subsidiaries and ownership
Company hierarchySubsidiaries4 records
LSK Global PS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LSK Global PS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LSK Global PS
What does LSK Global PS do?
LSK Global PS is a full-service Contract Research Organization (CRO) providing end-to-end clinical drug development services for pharmaceutical and biotech sponsors. The company delivers an integrated platform covering the entire clinical trial lifecycle—from drug development consulting, regulatory affairs, medical writing, and study start-up through Phase I–IV clinical operations, data management, biostatistics, pharmacovigilance, quality assurance, and post-marketing surveillance. Services are sold via custom project-based contracts negotiated through the Business Development department.
Is LSK Global PS a public or private company?
LSK Global PS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was LSK Global PS founded?
LSK Global PS was founded in 2000. It employs 251 to 500 people.
Where is LSK Global PS based?
LSK Global PS is headquartered in Seoul, South Korea, in the Asia region.
How does LSK Global PS make money?
Five revenue lines are on record. Clinical Trial Services are the primary driver. The others are regulatory Affairs Services, pharmacovigilance Services, education and Training Services and academic Research Services.
Who are LSK Global PS's main competitors?
Broad incumbents on record are Parexel International, ICON plc, Syneos Health, Labcorp Drug Development (Fortrea) and IQVIA Holdings. Direct peers are Medpace Holdings and MakroCare. CMIC Holdings is listed as a regional player. Emerging players are PSI CRO and Celerion.
Does LSK Global PS have an API?
No public API is recorded for LSK Global PS.
What industry is LSK Global PS in?
LSK Global PS's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.